Evidence map›Paper›PMID 34997299›Full record

ArticleAbdominal radiology (New York)2022

US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy.

Nathan Velarde, Antonio C Westphalen, Hao G Nguyen, John Neuhaus, Katsuto Shinohara, Jeffry P Simko, Peder E Larson, Kirti Magudia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Abdominal radiology (New York), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nathan VelardeDepartment of Radiology, University of California, San Francisco, San Francisco, CA, USA. Nathan.velarde@ucsf.edu.ORCID 0000-0002-2997-6504
Antonio C WestphalenDepartment of Radiology, Urology, and Radiation Oncology, University of Washington, Seattle, WA, USA.
Hao G NguyenDepartment of Urology, University of California, San Francisco, San Francisco, CA, USA.
John NeuhausDepartment of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Katsuto ShinoharaDepartment of Urology, University of California, San Francisco, San Francisco, CA, USA.
Jeffry P SimkoDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA.
Peder E LarsonDepartment of Radiology, University of California, San Francisco, San Francisco, CA, USA.
Kirti MagudiaDepartment of Radiology, Duke University, Durham, NC, USA.

Funding

NIH HHS NIBIB 5T32EB0011631-14
6 · The paper itself

Abstract

purposeTo identify predictors of when systematic biopsy leads to a higher overall prostate cancer grade compared to targeted biopsy. METHODS AND MATERIALS: 918 consecutive patients who underwent prostate MRI followed by MRI/US fusion biopsy and systematic biopsies from January 2015 to November 2019 at a single academic medical center were retrospectively identified. The outcome was upgrade of PCa by systematic biopsy, defined as cases when systematic biopsy led to a Gleason Grade (GG) ≥ 2 and greater than the maximum GG detected by targeted biopsy. Generalized linear regression and conditional logistic regression were used to analyze predictors of upgrade.

resultsAt the gland level, the presence of an US-visible lesion was associated with decreased upgrade (OR 0.64, 95% CI 0.44-0.93, p = 0.02). At the sextant level, upgrade was more likely to occur through the biopsy of sextants with MRI-visible lesions (OR 2.58, 95% CI 1.87-3.63, p < 0.001), US-visible lesions (OR 1.83, 95% CI 1.14-2.93, p = 0.01), and ipsilateral lesions (OR 3.89, 95% CI 2.36-6.42, p < 0.001).

conclusionSystematic biopsy is less valuable in patients with an US-visible lesion, and more likely to detect upgrades in sextants with imaging abnormalities. An approach that takes additional samples from regions with imaging abnormalities may provide analogous information to systematic biopsy.

Indexed as

Image-Guided BiopsyProstatic NeoplasmsHumansMagnetic Resonance ImagingMaleNeoplasm GradingProstateRetrospective StudiesImage-guided biopsyMagnetic resonance imagingProstate neoplasmsUltrasound

Identifiers

PMID34997299
PMCPMC8863714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.